Search Results

Earlier this year, I wrote a piece about TAMOF — thrombocytopenia-associated multiple organ failure — and the case for recognizing it as a TTP-like process driven by secondary ADAMTS13 deficiency. I described the lab pattern. I walked through the differential. I made what I believed was a compelling argument that TAMOF is underrecognized, and that plasma exchange is a rational intervention once the diagnosis is made. I stand by that piece. The pathophysiology is real. The lab pattern is real. The clinical scenarios I described are ones that pathologists and intensivists encounter regularly. But since writing it, I’ve spent more time with the literature surrounding TAMOF, and I’ve come to appreciate something I didn’t fully reckon with the first time around: the question isn’t just whether TAMOF is real. The question is whether TAMOF is useful — and that turns out to be a much harder thing to answer. The Case I Made In my earlier article, I described TAMOF as occupying an uncomfortable space between DIC, TTP, and sepsis-associated coagulopathy. The central idea was that systemic inflammation can drive a relative deficiency of ADAMTS13, leading to accumulation of ultra-large von Willebrand factor multimers and platelet-rich microthrombi in the microvasculature. The downstream effect looks like TTP — organ ischemia, thrombocytopenia, elevated LDH, sometimes schistocytes — even though the trigger is sepsis or inflammation rather than autoimmunity. I emphasized that the lab pattern tells the story: falling platelets, rising LDH, preserved coagulation parameters, and organ dysfunction out of proportion to hemodynamics. I argued that recognizing this pattern opens the door to therapeutic plasma exchange, and that missing it leaves patients undertreated. None of that is wrong, exactly. But it is incomplete. The Questions I Didn’t Ask The concept of TAMOF was primarily developed by Nguyen and Carcillo, with foundational work published in Critical Care  in 2006. From the beginning, TAMOF was described not as a single disease but as a clinical phenotype — an umbrella encompassing TTP, DIC, and secondary thrombotic microangiopathy in critically ill patients. The unifying feature was new-onset thrombocytopenia coinciding with multiple organ failure, and the proposed mechanism was microvascular thrombosis. This is where the first tension appears. If TAMOF includes DIC, TTP, and secondary TMA under one label, what does the label add? Each of those entities already has its own diagnostic criteria, its own pathophysiology, and — critically — its own treatment approach. DIC is a consumptive coagulopathy driven by tissue factor. TTP is an autoantibody-mediated deficiency of ADAMTS13. Secondary TMA is a broader category of inflammation-driven microangiopathy. These are not the same process. Grouping them under one name risks implying a mechanistic unity that does not exist. In my first article, I focused on the subset of TAMOF that behaves like TTP — the secondary TMA piece, where inflammation drives ADAMTS13 deficiency and platelet-vWF-mediated thrombosis predominates. That is a real phenomenon. But by calling it TAMOF rather than secondary TMA, I may have inadvertently adopted a framework that obscures more than it clarifies. The Evidence Problem The therapeutic implication of recognizing TAMOF is plasma exchange. This was central to my earlier piece: once you see the microangiopathy, the rationale for plasma exchange follows logically. Remove the ultra-large vWF multimers. Replenish ADAMTS13. Reduce inflammatory mediators. The biological plausibility is sound. The evidence base, however, is thin. The landmark pediatric trial randomized just ten children — five to plasma exchange, five to standard therapy. The results were encouraging: plasma exchange restored ADAMTS13 activity and was associated with organ failure resolution. But a trial of ten patients, however well-designed, cannot establish standard of care. Subsequent studies have been retrospective, observational, or limited to small cohorts. The Turkish TAMOF Network described outcomes in 42 children but could not even measure ADAMTS13 levels due to unavailability of the assay. A prospective multicenter experience published more recently found lower 28-day mortality in children treated with plasma exchange, but the authors themselves concluded that a randomized clinical trial is necessary to establish a causal relationship. The American Society for Apheresis gives plasma exchange in sepsis with multiple organ failure a Category III recommendation — meaning the optimum role is not established and decision-making should be individualized. This is not an endorsement. It is an acknowledgment that we don’t know enough. The ADAMTS13 Problem In my earlier piece, I described ADAMTS13 as spanning a wide range in TAMOF and cautioned against rigid thresholds. I still think that’s right. But I underappreciated a more fundamental issue: we do not yet know whether reduced ADAMTS13 in sepsis is the cause of organ dysfunction or simply a marker of disease severity. This distinction matters enormously. If reduced ADAMTS13 is pathogenic — if it is actively driving microthrombi formation and organ ischemia — then replenishing it through plasma exchange is a targeted intervention. But if ADAMTS13 is reduced because the patient is severely ill, because inflammation broadly suppresses hepatic synthesis and accelerates consumption of many proteins, then treating the ADAMTS13 level may be treating a surrogate rather than the disease itself. Moreover, ADAMTS13 activity in TAMOF is typically reduced but not severely deficient. In classic TTP, levels are usually below 10%. In sepsis-associated secondary TMA, levels are more often in the 20–60% range. This is an important gray zone. Plenty of critically ill patients with sepsis have mildly reduced ADAMTS13, and most of them do not have a clinically meaningful microangiopathic process. The specificity of this biomarker, in this context, is genuinely uncertain. The Diagnostic Boundary Problem TAMOF is diagnosed by a triad: new-onset thrombocytopenia below 100,000, at least two failing organs, and elevated LDH. The problem is that this triad describes an enormous proportion of critically ill septic patients. Thrombocytopenia in the ICU is common — present in up to 40–50% of patients, depending on the threshold used. LDH elevation is nearly ubiquitous in critical illness. And organ failure is, almost by definition, why these patients are in the ICU in the first place. If the diagnostic criteria capture too many patients, the label loses its power to identify those who would specifically benefit from targeted intervention. A diagnosis that applies to half the ICU is not a diagnosis. It is a description. What I Think Now I want to be careful here, because I don’t think the answer is that TAMOF is meaningless or that my earlier article was misguided. The pathophysiology I described — inflammation-driven ADAMTS13 deficiency leading to platelet-vWF-mediated microvascular thrombosis — is supported by autopsy data, by biomarker studies, and by the clinical observation that some septic patients develop a microangiopathic picture that does not fit neatly into DIC. That phenomenon is real, and it deserves a name. But I think the name might be doing some work that the evidence hasn’t earned yet. TAMOF as an umbrella term bundles together mechanistically distinct processes and implies they share a common therapeutic target. TAMOF as a diagnostic entity relies on criteria so broad that they risk capturing patients who don’t have a true microangiopathy at all. And TAMOF as a justification for plasma exchange rests on studies that, while promising, remain small, largely retrospective, and without a definitive randomized trial. What I wrote before was an argument for recognition — for seeing the pattern and acting on it. What I’d add now is an argument for precision. The lab pattern I described is still the right place to start. Converging signals of microangiopathy in a septic patient should prompt the question: is there a thrombotic microangiopathic process driving this patient’s organ failure? But the answer to that question should lead to a specific diagnosis — secondary TMA, DIC, or something else — not to a catch-all label that may prematurely close the differential. The Lab’s Role, Revisited I ended my first article with the line: “TAMOF is not rare because it is uncommon. It is rare because we don’t look for it.” I still believe that’s true — but I’d frame it differently now. What’s underrecognized isn’t necessarily TAMOF as a discrete entity. What’s underrecognized is the broader phenomenon of secondary thrombotic microangiopathy in the critically ill, and the role that laboratory medicine plays in distinguishing it from DIC, from “just sepsis,” and from true TTP. That distinction requires more than a label. It requires the kind of contextual interpretation that has always been the core competency of the pathologist: not just reporting numbers, but assembling them into a story that changes management. The controversy around TAMOF is not really about whether the biology is real. It is about whether we have the right framework to describe it, the right criteria to diagnose it, and the right evidence to treat it. On all three counts, the honest answer is: not yet. But “not yet” is not the same as “no.” It means we have more work to do. And for those of us in the lab, that work starts with being willing to question our own frameworks — even the ones we just finished building.

When clinicians say, “I called the blood bank,” they usually mean one of two things: they need blood products, or something about a transfusion doesn’t feel right. Those are not the same situation — and they are not handled the same way. At most institutions, the blood bank laboratory and the Transfusion Medicine service operate as an integrated system. They overlap. They collaborate constantly. But they serve different functions. That difference matters. The Blood Bank: Technical and Operational Safety The blood bank laboratory is responsible for: ABO/Rh typing and antibody screens Crossmatching and compatibility testing Investigating serologic incompatibilities Preparing and issuing blood components Maintaining regulatory and quality standards It is the operational engine of transfusion safety. It ensures the right product reaches the right patient efficiently and in compliance with strict regulatory frameworks. But laboratory testing alone does not answer every clinical question. Transfusion Medicine: Clinical Judgment in Real Time The Transfusion Medicine service provides physician-level consultation when transfusion decisions become complex or when adverse events occur. We are consulted for: Suspected transfusion reactions Hemolysis or unexpected serologic findings Complex alloimmunization cases Risk–benefit discussions in high-risk scenarios Questions about product selection beyond routine ordering When a patient develops hypotension, hypoxia, fever, or laboratory evidence of hemolysis during or after a transfusion, the question is no longer simply, “What do the labs show?” It becomes: Is this TRALI, TACO, hemolysis, sepsis, or something unrelated? Should additional products be given? Does this event require reporting or product quarantine? The laboratory can detect hemolysis. It cannot diagnose TRALI. These are clinical determinations that require integration of history, timing, exam findings, imaging, and laboratory data. When to Involve Transfusion Medicine A practical rule of thumb: If you are unsure whether what you are seeing “counts” as a transfusion reaction — involve us. Early consultation allows: Real-time clinical assessment Guidance on stopping versus continuing transfusion Appropriate laboratory evaluation Accurate documentation in the EMR Prevention of downstream complications Waiting until the picture is unmistakable often means the patient has already deteriorated further than necessary. The threshold should be low — particularly for severe allergic reactions, suspected hemolysis, respiratory compromise, or unexplained instability during transfusion. Why Role Clarity Matters Conflating the laboratory function with clinical consultation can create blind spots. If a reaction is reported only as a technical issue, important clinical context may be missed. Without coordinated physician involvement, transfusion reactions are more likely to be under-recognized, misclassified, or inconsistently documented. That affects more than a single patient encounter. It impacts hemovigilance data, quality reporting, and our ability to learn from adverse events. Transfusion is one of the most common procedures performed in hospitalized patients. It is also one of the few therapies that requires laboratory and clinical teams to function as a tightly integrated unit in real time. Clear roles within that integration improve patient safety. A Collaborative Model This is not about separation. It is about alignment. The blood bank laboratory ensures technical and regulatory safety. The Transfusion Medicine physician provides clinical oversight and interpretation. They are complementary functions within the same safety system. If you are ordering routine blood for a stable patient, the laboratory will manage the process seamlessly. If a transfusion becomes clinically complicated — or something simply does not make sense — physician-level Transfusion Medicine consultation should be part of the response. Transfusion Medicine is not just a laboratory process. It is a clinical service embedded within it. And when in doubt, call.

There are moments in transfusion medicine when the most uncomfortable part of a case isn’t the serology — it’s the realization that the literature can’t quite tell you what to do. Recently, on service, I encountered a patient with a rare A subgroup and a cold-reacting anti-A1. Genotyping suggested either an Aw allele or an Ael allele. The immediate question was practical and deceptively simple: Is it safe to transfuse group A red cells, or should we restrict the patient to group O? What followed was a familiar exercise for anyone who practices in the margins of evidence: reading case reports, revisiting mechanism, and trying to decide how much uncertainty is acceptable when the downside is fatal hemolysis. Along the way, one thing became clear: not all weak A phenotypes are biologically — or clinically — interchangeable. In particular, A3 is not the same as Aw, and neither is the same as Ael. Yet they are often discussed together, sometimes implicitly treated as a single category. That shortcut matters. The problem with “weak A” as a single bucket In everyday blood bank practice, weak A phenotypes are often grouped together for operational reasons: they may present as ABO discrepancies, require additional testing, or trigger conservative transfusion strategies. But biologically, these phenotypes arise through very different mechanisms, and those differences shape how we should think about transfusion risk. Here’s a simplified comparison. A3 vs Aw vs Ael — why the distinction matters Feature A3 Aw Ael Typical serologic pattern Mixed-field agglutination with anti-A Weak or very weak anti-A; variable No agglutination with anti-A Detectable without elution? Yes Often yes (weak) No Detectable by adsorption–elution Usually not needed Sometimes Required Underlying mechanism Reduced or mosaic expression; often promoter/splicing effects Hypomorphic A transferase with allele-in-trans–dependent expression Near-null expression, often due to early truncation of A transferase Degree of A antigen exposure Present on a subset of RBCs Variable; can be extremely low Trace only Evidence base for transfusion safety Relatively robust (dominates “weak A” literature) Sparse, case-based Extremely limited Theoretical risk of allo-anti-A Low Uncertain Plausible (no incidence data) Why A3 is different A3 is classically defined by mixed-field agglutination with anti-A: some red cells express A antigen clearly, others do not. Importantly, A antigen is present and visible without elution. From an immunologic standpoint, this matters. The immune system has likely been exposed to A antigen throughout life. Unsurprisingly, much of the reassuring transfusion experience for “weak A” phenotypes comes from cohorts dominated by A3 and similar variants. When people say, “We transfuse A all the time in weak A and nothing happens,” they are often — implicitly — talking about A3. Ael: a fundamentally different phenotype Ael occupies the opposite end of the spectrum. These phenotypes typically arise from premature termination codons early in the ABO A transferase gene. Routine serology shows no A antigen at all; detection requires adsorption–elution, and even then only trace amounts are found. In practical terms, most circulating red cells are immunologically indistinguishable from group O. Does this mean patients with Ael will  form allo-anti-A? No one knows. The literature does not report an incidence. But mechanistically, the conditions that support immune tolerance to A antigen are clearly not the same as in A1, A2, or A3 phenotypes. This is where the phrase “absence of evidence is not evidence of absence”  stops being academic. Aw: the uncomfortable middle Aw phenotypes are what make this topic genuinely hard. Unlike A3, Aw is not a mixed-field phenotype by default. And unlike Ael, it is not uniformly silent. Instead, expression depends heavily on the allele in trans. One of the most striking demonstrations of this comes from maternal–child discordance cases, where the same  Aw allele produced: essentially no detectable A antigen when paired with an O allele, and robust A expression when paired with a B allele. In other words, Aw can look immunologically like Ael in one context and A2 or stronger in another. When you encounter Aw in the blood bank, you are not just dealing with “weak A.” You are dealing with context-dependent A expression, and that uncertainty follows you into transfusion decisions. What about hemolysis and antibodies? Most anti-A1 antibodies are cold, IgM, and clinically insignificant. That’s true — until it isn’t. Case reports exist of hemolytic transfusion reactions involving anti-A1 when thermal amplitude is broad or when additional risk factors are present. These cases are rare, but they loom large precisely because the denominator is so poorly defined. What we don’t  have are: incidence data for allo-anti-A formation in Ael or Aw individuals, outcome studies stratified by molecular subgroup, or prospective evidence that transfusing group A is uniformly safe across all weak A genotypes. So when clinicians default to group O in these cases, it’s not ignorance. It’s an acknowledgment of uncertainty. Conservatism isn’t a failure of evidence — it’s stewardship In my case, we chose to transfuse group O red cells while we waited for expert input. That decision wasn’t driven by panic or dogma. It was driven by a simple question: If I’m wrong, what happens to the patient? In transfusion medicine, the cost of being wrong is asymmetric. Hemolysis is rare — until it isn’t — and when it happens, it’s unforgettable. Until we have better data, it is reasonable to treat A3, Aw, and Ael differently, even if our SOPs and textbooks sometimes collapse them into the same category. Closing thought Somewhere between genotype, phenotype, and patient safety is a space where we practice medicine without a net. That’s not a failure of science. That’s where judgment lives. And sometimes, judgment looks like a unit of group O. Please see this related post for an update on this case: https://www.bloodbytesbeyond.com/post/anti-a1-in-practice-not-in-theory

After I published a recent post about a patient with a rare A subgroup and a cold-reacting anti-A1, I did what transfusion medicine quietly trains us all to do when the literature runs thin: I picked up the phone. The case itself was straightforward to describe and uncomfortable to decide. Genotyping suggested either an Aw  allele or an Ael  allele. Serology favored Aw , with faint agglutination detectable without elution. The patient also had a cold-reacting anti-A1. The question was simple and not at all academic: should we transfuse group A red cells, or restrict the patient to group O? In the absence of clear guidance, we chose conservatively while seeking expert input. That decision felt reasonable — but incomplete. So I reached out to colleagues at a reference laboratory to ask how they actually think about cases like this, not in theory, but in practice. What the Literature Teaches — and Where It Stops If you search anti-A1 and hemolysis, you will find what all of us find: case reports. Some are dramatic. A few involve hemolytic transfusion reactions. Many emphasize the same features — broad thermal amplitude, high titers, or unusual clinical contexts such as malignancy. What you will not find are incidence data. You won’t find outcome studies stratified by molecular subgroup. You won’t find a denominator large enough to tell you how often cold-reacting anti-A1 actually causes harm in routine transfusion practice. Case reports are essential—they define what can  happen. But they are also blunt instruments. They warn us without telling us how often to expect trouble, or how to weigh that risk against competing obligations like inventory stewardship. That gap is where reference labs live. What the Reference Lab Actually Looks At One of the most useful things about consulting a reference laboratory is learning which variables matter most  when time and data are limited. In this case, three themes came up repeatedly. 1. Thermal amplitude and titer matter more than genotype In practice, the single most important question is not whether the patient has Aw  versus Ael , but whether the anti-A1 reacts at 30 °C or higher. Cold-reacting anti-A1 antibodies that react only below 30 °C are overwhelmingly benign in real-world experience. Hemolysis in this setting is extraordinarily rare, particularly in otherwise stable patients. When reactions do occur, they tend to involve antibodies with broader thermal amplitude or very high titers that permit binding at warmer temperatures. This is not because genotype is irrelevant, but because thermal amplitude and titer are the only tools we currently have that correlate, however imperfectly, with clinical significance. 2. Malignancy-associated cases don’t generalize well Several of the most concerning reports of anti-A1–mediated hemolysis come from patients with malignancy, particularly myelodysplastic syndromes. These cases behave differently for a reason. In malignancy, the ABO glycosyltransferase genes may be epigenetically silenced or otherwise disrupted. Antigen expression can change or disappear entirely, and patients may transiently form potent antibodies against antigens they once expressed. These antibodies can be atypical, high-titer, and clinically significant — and may abate once the underlying disease is treated or after transplant. Those cases are real, but they are not representative of the average patient with a cold-reacting anti-A1. Treating them as such inflates perceived risk. 3. Group A is transfused more often than people realize Perhaps the most grounding insight was this: reference labs see these cases frequently, and group A red cells are routinely transfused to patients with cold-reacting anti-A1 without incident. That comfort does not come from theory. It comes from volume—from seeing the same scenario play out safely again and again. When reactions are limited to temperatures below 30 °C and the patient is not undergoing hypothermia or critically ill, the expectation is that transfusion will be tolerated. Group O remains an option — but not a default. Where Conservatism Still Makes Sense None of this means that caution is misguided. In fact, reference labs are often more  conservative in specific situations: Patients who are critically ill or have minimal physiologic reserve Antibodies with reactivity approaching 30 °C Very high titers, even if technically “cold” Planned hypothermia or cardiac surgery In those contexts, avoiding even low-grade hemolysis may matter more than inventory conservation, and the threshold for using group O appropriately drops. The key distinction is that conservatism becomes a choice , not an automatic rule. Judgment Is a Team Sport Case reports teach us what can go wrong. Reference labs teach us how often it does — and under what conditions. Clinicians have to integrate both, along with patient context and resource stewardship, to make decisions that are defensible even when the evidence is incomplete. That’s not a failure of science. It’s the practice of medicine. Sometimes, after all that, the answer is still group O. But now, at least, I know why—and when it doesn’t have to be.

Today we had a case that many transfusion services will recognize. A patient scheduled for surgery requested a directed blood donation. The reason given was concern about receiving blood from donors who had received a COVID-19 vaccine. The answer was no. She returned with a revised request: this time citing religious preference and psychological comfort. Again, the answer was no. Afterward, I had a long discussion with a resident — thoughtful, patient-centered, and clearly uncomfortable with refusing a request framed in ethical language. I don’t think I convinced them. And that matters, because this is exactly the kind of scenario where kindness  and ethics  feel deceptively close, and where “just accommodating” can feel easier than holding the line. So let’s be explicit about why the answer was no—and why it needed to be. What the Evidence Actually Says About COVID Vaccination and Blood Safety The fear driving these requests is understandable—but it is not evidence-based. There is no evidence that blood from donors who were vaccinated against COVID-19—or previously infected with SARS-CoV-2—poses increased risk to transfusion recipients. The strongest data come from a large recipient-linked study published in Transfusion  in 2025 (Roubinian et al.). Investigators examined 7,773 transfusion recipients across 8,715 hospitalizations, directly linking over 34,000 plasma and platelet units to donor vaccination and infection status. They assessed outcomes people worry about most: thrombosis, increased respiratory support, and hospital mortality. They found no association — not with vaccinated donors, not with previously infected donors, not with recent vaccination, recent infection, or high antibody titers (Roubinian et al., Transfusion , 2025). Concerns about transfusion-transmitted SARS-CoV-2 have likewise failed to materialize. While viral RNA can be transiently detected in blood during infection, infectious virus has not been recovered, and no cases of transfusion-transmitted COVID-19 have been documented. This is why donor vaccination status is not tracked or used in blood allocation. So when patients request “non-vaccinated blood,” they are not asking for something safer. They are asking for something different , based on a belief that the data do not support. What Directed Donation Is Actually For Directed donation exists—but for narrow medical reasons, not reassurance. Historically, it was used before modern infectious disease testing. Today, it is reserved for specific clinical indications, such as: Patients with rare blood types or antigen profiles Situations where compatible community donors are unavailable Selected pediatric or immunologic scenarios where compatibility constraints are real Outside of these circumstances, directed donation does not improve safety. In fact, it often makes things worse. A 2025 multidisciplinary consensus analysis in Annals of Internal Medicine  (Jacobs et al.) concluded that directed donation for nonmedical reasons — such as donor vaccination status or personal belief — introduces patient safety risks, operational burden, and societal harm without evidence of benefit. Why Directed Donation Increases Risk and Cost (Even When Everyone Means Well) The most persistent misconception about directed donation is that it is, at worst, harmless. It is not. Directed donation systematically increases risk, cost, and error—and it does so in predictable ways. First, donor risk. Directed donations disproportionately rely on first-time donors, who have consistently higher rates of infectious disease marker positivity than repeat community donors (Dorsey et al., Transfusion , 2013). In addition, directed donors are often under emotional or social pressure, which reduces the accuracy of donor health-history reporting—critical because all testing has a window period (Jacobs et al., Ann Intern Med , 2025). Second, immunologic risk. When directed donors are family members, additional hazards appear: HLA alloimmunization, transfusion-associated graft-versus-host disease (necessitating irradiation), TRALI risk, and complications relevant to future transplantation or pregnancy (Jacobs et al., 2025; Weaver et al., Pediatrics , 2023). Community blood is deliberately immunologically “boring.” Directed blood is not. Third, error and logistics. Modern transfusion safety depends on standardization. Directed units require special scheduling, labeling, tracking, storage, and coordination across multiple systems. Each deviation from routine workflow increases the risk of mislabeling, misidentification, expiration, delay, or waste. This is a human-factors problem, not a personnel problem (Jacobs et al., 2025). Fourth, reliability. Directed donation assumes ideal timing: donors qualify, donate on schedule, units clear testing, surgeries proceed as planned, and blood needs match exactly. In reality, donors are deferred, units expire, surgeries change, and emergencies don’t wait. When directed units fail, patients still receive community blood — often under more urgent conditions. Fifth, cost. Directed donation is substantially more expensive: additional recruitment, separate processing and inventory, irradiation, staff time, and higher wastage rates. Who pays is often unclear — the patient, the hospital, the blood center, or all three. There is no evidence these costs improve outcomes (Jacobs et al., 2025). Finally, system-level harm. Blood is a shared resource. Normalizing directed donation diverts donors from the community supply, worsens shortages, delays care, and privileges patients with social capital and access. It also implicitly validates misinformation — suggesting that some donors’ blood is inherently safer without evidence. Where Autonomy Applies—and Where It Does Not This is where the ethical line must be drawn clearly. Religious objection to blood transfusion itself is ethically valid. Competent adults may refuse blood products entirely, even if refusal carries serious risk. That is autonomy. But autonomy does not extend to requesting blood from donors with preferred personal characteristics absent medical necessity. Religion and moral frameworks may motivate people to donate blood altruistically to the community supply (Maghsudlu & Nasizadeh, 2011; Gillum & Masters, 2010). They do not create a right to receive blood from a chosen category of donors. Once belief-based donor preferences are accommodated, medicine implicitly endorses them. That opens the door to discriminatory requests — vaccination status today, race or gender tomorrow — and undermines decades of ethical progress in transfusion medicine (Jacobs et al., 2025). Respecting patients does not require validating unfounded fears or restructuring safety systems around them. The Uncomfortable Truth What made this case difficult wasn’t the policy—it was the discomfort. Saying no feels unkind. Especially when requests are reframed in ethical language. Especially when anxiety is real. Especially when the temptation is to say, “Why not just this once?” But “just this once” is never neutral. Every exception teaches something: about evidence, about safety, about whose fears medicine will legitimize. Transfusion medicine exists precisely because we learned—often painfully—that systems protect patients better than intentions. So yes, we said no. Twice. Not because we dismiss religion. Not because we don’t care about comfort. But because our ethical obligation is to protect patients, preserve trust in the blood supply, and practice medicine grounded in evidence — not fear. And sometimes, that means holding the line clearly, calmly, and without apology. References Roubinian NH, Greene J, Spencer BR, et al. Blood donor SARS-CoV-2 infection or vaccination and adverse outcomes in plasma and platelet transfusion recipients. Transfusion.  2025;65(3):485–495.doi:10.1111/trf.18159 Jacobs JW, Booth GS, Lewis-Newby M, et al. Medical, societal, and ethical considerations for directed blood donation in 2025. Annals of Internal Medicine.  2025;178:1021–1026.doi:10.7326/ANNALS-25-00815 Dorsey KA, Moritz ED, Steele WR, et al. A comparison of HIV, HCV, HBV, and HTLV marker rates for directed versus volunteer blood donations to the American Red Cross, 2005–2010. Transfusion.  2013;53:1250–1256.doi:10.1111/j.1537-2995.2012.03904.x Weaver MS, Yee MEM, Lawrence CE, Matheny Antommaria AH, Fasano RM. Requests for directed blood donations. Pediatrics.  2023;151(3):e2022058183.doi:10.1542/peds.2022-058183 Maghsudlu M, Nasizadeh S. Iranian blood donors’ motivations and their influencing factors. Transfusion Medicine.  2011;21(4):247–255.doi: 10.1111/j.1365-3148.2011.01077.x Gillum RF, Masters KS. Religiousness and blood donation: Findings from a national survey. Journal of Health Psychology.  2010;15(2):163–172.doi: 10.1177/1359105309345171

Schedules, Evidence, and Real-World Alternatives One of the most common questions I get from residents rotating through apheresis or transplant is deceptively simple: “How often do we do extracorporeal photopheresis?” The honest answer is: it depends —and not in a hand-wavy way. ECP schedules vary by disease, acuity, and goals of therapy, and the evidence actually supports very different approaches for acute GVHD, chronic GVHD, and cutaneous T-cell lymphoma. Add in newer targeted agents like ruxolitinib and belumosudil, and the question becomes not just how often , but why ECP at all . Let’s walk through what we know, what we don’t, and how to explain this clearly to trainees. First: What an “ECP cycle” actually means Before getting into frequency, it helps to define the unit of treatment. Traditionally, one ECP cycle = treatment on two consecutive days. This convention dates back to the original FDA-approved protocols for cutaneous T-cell lymphoma and has persisted across indications. UK consensus statements and most international guidelines still define ECP this way—whether the cycles are weekly, every two weeks, or monthly. Importantly, this two-day structure is not based on randomized comparisons showing superiority over alternate-day or single-day schedules. It’s a mix of historical precedent, logistics, and immunologic plausibility: delivering two closely spaced infusions of apoptotic, photoactivated leukocytes may amplify the tolerogenic signal that drives regulatory T-cell expansion. There are  data supporting single-day, higher-volume ECP protocols—especially when access, staffing, or infection risk is a concern—but we do not have evidence that every-other-day (QOD) schedules improve outcomes. In practice, QOD would increase patient burden without a demonstrated benefit. So when residents ask, “Why two days in a row?” the most accurate answer is: Because that’s how ECP has been studied, standardized, and operationalized—not because it’s the only biologically plausible option. Acute GVHD: Intensive up front, then stop For acute GVHD, the signal is fairly consistent across studies: front-load the intensity. Most consensus guidelines support: Weekly ECP, usually as two consecutive days per week For about 8 weeks With no routine maintenance once a response is achieved Real-world and pediatric studies vary in how aggressive they start—some using twice-weekly or even three-times-weekly treatments early on—but the theme is the same: hit hard early, then taper or discontinue. Response rates across these studies fall in the 55–65% range early, with higher cumulative response by 8–12 weeks. The key teaching point for trainees is this: Acute GVHD behaves like an inflammatory emergency. ECP works best when used intensively and early—not as a slow burn. Chronic GVHD: Lower intensity, much longer runway Chronic GVHD is a different disease biologically and clinically, and ECP schedules reflect that. Typical regimens include: Two consecutive days every 2 weeks With tapering to monthly treatments based on response Over 12–18 months, sometimes longer Large series using bimonthly schedules report response rates approaching 80–90%, especially for skin and mucocutaneous disease. Importantly, longer duration of therapy appears to correlate with better outcomes, even when early responses are modest. This is a critical mindset shift for residents: Chronic GVHD is not about rapid control—it’s about sustained immune retraining. Stopping ECP too early is one of the most common reasons for perceived “failure.” CTCL / Sézary syndrome: Slow and steady For cutaneous T-cell lymphoma, ECP remains a preferred therapy in major guidelines, either alone or in combination. The classic approach is: Two consecutive days every 2–4 weeks With the expectation that responses take months, not weeks This is often frustrating for trainees (and patients), but it mirrors the biology of the disease. CTCL responds to cumulative immunomodulation, not rapid cytoreduction. “If ruxolitinib works so well… why ECP?” This is the question residents are really  asking now. Ruxolitinib is FDA-approved and guideline-endorsed as first-line therapy for steroid-refractory acute and chronic GVHD. Belumosudil has strong data in later-line chronic GVHD. So where does ECP fit? The short answer: toxicity, durability, and complementarity. Ruxolitinib (JAK1/2 inhibition) is highly effective but commonly causes cytopenias and increases infection risk. Belumosudil (ROCK2 inhibition) targets fibrosis and immune imbalance, particularly useful in sclerotic chronic GVHD. ECP, by contrast, is remarkably safe—minimal cytopenias, low infection risk, and steroid-sparing over time. That safety profile matters. ECP is often favored: When cytopenias limit ruxolitinib When infections are active or recurrent As combination therapy, where emerging data suggest better long-term control than ruxolitinib alone In other words, ECP isn’t obsolete—it’s strategic. What I tell residents to remember If I had to distill this into a few teaching pearls: ECP is not one schedule—it’s a framework. Acute GVHD → intensive, short-term. Chronic GVHD → prolonged, maintenance-oriented. Two consecutive days is convention, not dogma. ECP’s value is safety, durability, and synergy—not speed. And perhaps most importantly: If you’re asking how often to do ECP, you’re already asking the right question. The answer lives at the intersection of disease biology, patient tolerance, and what you’re trying to achieve.

Extracorporeal photopheresis (ECP) has one of the best safety reputations in procedural medicine. It’s been used for decades. Hundreds of thousands of treatments. Indications ranging from cutaneous T-cell lymphoma to chronic graft-versus-host disease. And yet, every so often, the same question resurfaces: Does ECP increase the risk of thrombosis? The short answer is: there is a signal, but it’s small, context-dependent, and often misunderstood. The longer answer is more interesting—and more useful. Where the concern comes from In 2018, the FDA issued a letter to healthcare providers warning of reported cases of venous thromboembolism (VTE), including pulmonary embolism, in patients undergoing ECP with the THERAKOS CELLEX system. That sentence alone has done a lot of quiet work over the years. What often gets lost is why  the FDA issued the letter and what it actually said . The warning was based on post-marketing reports, not on prospective trials or large cohort studies. The FDA described seven pulmonary emboli and two deep vein thromboses, all occurring in patients treated for chronic GVHD. Two of the pulmonary emboli were fatal. The mean time to event was about 1.7 days, leading to the phrasing that events occurred “during or shortly after” treatment sessions. Importantly, the FDA did not conclude that ECP causes thrombosis. The language was careful: ECP may  increase risk, based on timing and clustering in a vulnerable population. That distinction matters. What the published literature shows (and doesn’t) If you go looking for thrombosis in the ECP literature, you’ll find… very little. Across more than 30 years of published experience: Thrombotic events are rare Most reported cases are catheter-associated, not systemic Large case series and reviews consistently emphasize ECP’s excellent safety profile Coagulation parameters remain stable during treatment, even with long-term therapy Laboratory studies show platelet activation after UVA/8-MOP exposure—but without aggregation or downstream thrombotic effects In pediatric cohorts, multicenter studies, and long-term follow-up reports, thrombosis appears as an isolated complication, not a recurring pattern. That doesn’t mean the FDA signal was wrong. It means the signal exists in a space the literature hasn’t fully interrogated. The missing denominator problem One of the hardest things about post-marketing safety signals is that they arrive without context. We don’t know: How many total ECP treatments occurred during the reporting window Whether events clustered around central venous access How immobility, inflammation, infection, or baseline hypercoagulability contributed Whether similar patients not receiving ECP had comparable short-term VTE rates And chronic GVHD patients—who made up all reported cases—already carry a high baseline risk of thrombosis. When a population is fragile enough, even a neutral intervention can appear suspicious if you look only at timing. So where does that leave us? A reasonable, evidence-based position looks something like this: ECP is not a high-thrombosis procedure There is a small regulatory safety signal, concentrated in a very high-risk population Timing alone does not establish causality Access-related thrombosis likely explains a meaningful fraction of reported events Clinicians should remain alert—but not alarmist This is not a story of a dangerous therapy being uncovered. It’s a story of how safety signals emerge, how they should be interpreted, and how nuance gets flattened over time. Why this matters ECP is often used when options are limited. Overstating risk can quietly narrow access to a therapy that is otherwise well-tolerated and effective. At the same time, ignoring regulatory signals entirely isn’t good medicine either. The work, as always, is in the middle: understanding who  might be at risk, when  vigilance matters most, and how  to contextualize rare events without letting fear do the thinking. Bottom line: If thrombosis were a common or intrinsic complication of ECP, we would know by now. What we have instead is a small, signal-level warning that deserves clarity—not amplification. And clarity is something we can still build.

How the BEST Criteria Updated a Decade-Old AABB Approach to Septic Transfusion Reactions One of the most uncomfortable questions in transfusion medicine is deceptively simple: When should we culture the patient and the blood product after a transfusion reaction? Culture too often, and you trigger false positives, unnecessary lookbacks, and wasted resources.Culture too conservatively, and you risk missing a true septic transfusion reaction — one of the most dangerous complications we manage. For years, many institutions have relied on guidance from an AABB Association Bulletin published in 2014. But in 2019, a large multicenter study fundamentally challenged whether those criteria are sensitive enough for real-world practice. This post walks through what changed, why it matters, and what the tradeoff actually is. The AABB 2014 Bulletin: Safety Through Clinical Vigilance The 2014 AABB Association Bulletin on suspected bacterial contamination of platelets was written with a clear goal:don’t miss sepsis. Its framework is intentionally broad and clinically driven. In short, it recommends investigation when: A patient develops fever ≥38°C with a ≥1°C rise, plus  at least one associated symptom (rigors, hypotension, tachycardia, dyspnea, etc.), or There is any  clinical change that raises concern for sepsis — even without fever Importantly, the bulletin acknowledges: Fever may be absent in neutropenic or immunosuppressed patients Antipyretics may blunt temperature rise Symptoms may be delayed This guidance reflects its era. In 2014, the dominant concern was under-recognition of septic transfusion reactions, especially with gram-positive organisms. The solution was education, vigilance, and a low threshold to act. What the bulletin did not  do was define: Objective thresholds for hypotension or tachycardia How to systematically account for antipyretic use How well these criteria actually perform in practice That gap mattered more than we realized. The Problem: How Well Do the AABB Criteria Actually Work? In 2019, investigators from the BEST (Biomedical Excellence for Safer Transfusion) Collaborative asked a hard question: If we apply the AABB criteria to real-world transfusion reactions, how many culture-positive cases do we actually detect? Using data from nearly 800,000 transfusions across 20 centers, they found that the answer was… not many. When evaluated empirically: The AABB criteria detected only ~40% of culture-positive reactions The majority of reactions that ultimately yielded positive cultures never met AABB triggers Reliance on fever and subjective symptom reporting was a major limitation In other words, the system was doing exactly what it was designed to do — but that design was missing cases. The BEST Criteria: Trading Specificity for Sensitivity (On Purpose) Rather than discarding the AABB framework, the BEST investigators asked: What small, evidence-based changes would catch more cases? They tested three modifications, all of which improved detection: 1. Isolated High Fever Counts A temperature ≥39°C with a ≥1°C rise triggered culture even without other symptoms. Why? Because multiple international criteria already recommended this — and AABB did not. 2. Objective Vital Sign Definitions Instead of relying on checkbox reporting: Hypotension required both an absolute BP threshold and a percentage drop Tachycardia required ≥100 bpm and a significant increase from baseline This mattered because provider-reported vital sign abnormalities were frequently inaccurate. 3. Antipyretics Matter If a patient received antipyretics before transfusion, absence of fever could not be used to rule out sepsis when other concerning signs were present. This was not a philosophical change — it reflected basic physiology. Did It Work? Yes — and predictably. When all three modifications were combined into the BEST criteria: Sensitivity improved to ~70–75% Specificity decreased to ~45% Crucially: there were no cases detected by AABB that BEST missed In other words, BEST caught substantially more potential septic reactions — at the cost of more cultures and more false positives. This was not an accident. It was a conscious tradeoff. The Real Debate: False Positives vs Missed Sepsis Critics of broader culturing thresholds often raise legitimate concerns: Positive product cultures trigger supplier notification Co-components may be quarantined or destroyed Many positive cultures do not correlate with patient infection All of that is true. But the BEST authors make a different argument: In a passive surveillance system, missing cases is the greater danger. Septic transfusion reactions are rare, difficult to adjudicate, and often masked by critical illness. Fever is unreliable. Cultures are imperfect. But hypotension requiring pressors, shock, or unexplained deterioration are not benign signals, even when temperature is normal. The BEST criteria reflect a shift from: “Culture when sepsis is obvious” to “Culture when sepsis is plausible and high-risk.” Where This Leaves Us The AABB 2014 bulletin is not wrong .It is incomplete by modern standards. The BEST criteria don’t replace clinical judgment — they formalize what experienced clinicians already know: Fever is not required for sepsis Antipyretics obscure key signals Objective thresholds matter Sensitivity matters more than comfort when stakes are high Institutions now face a choice: Accept fewer cultures and higher miss rates, or Accept more cultures to reduce the risk of missing a true septic transfusion reaction That choice is about risk tolerance, not right vs wrong. But it should be made using current evidence, not decade-old assumptions. Bottom line If you are still relying solely on fever-centric AABB criteria from 2014, you are almost certainly missing cases. The BEST criteria offer a data-driven update that reflects how septic transfusion reactions actually present — messy, masked, and dangerous. In transfusion medicine, that tradeoff is worth naming out loud.

It was a routine service morning — until it wasn’t. The patient wasn’t crashing in a cinematic way. No massive bleeding. No dramatic hypotension. But the labs were drifting in a direction that felt wrong: platelets falling, creatinine creeping, LDH elevated, hemoglobin sliding just enough to notice. Organ dysfunction without a single unifying explanation. Somewhere between the pattern and the unease it produced, the diagnosis surfaced quietly: TAMOF. What TAMOF Is — and Why It’s Easy to Miss Thrombocytopenia-associated multiple organ failure (TAMOF) occupies an uncomfortable space between entities we think we understand well: DIC, TTP, and sepsis-associated coagulopathy. Because it doesn’t fit cleanly into any of them, it is often mislabeled — or not labeled at all. At its core, TAMOF is a secondary thrombotic microangiopathy driven by systemic inflammation. Systemic inflammation leads to a relative decrease in ADAMTS13, which results in the accumulation of ultra long vWF multimers. When regulatory capacity is insufficient for that inflammatory burden, platelet-rich microthrombi form in the microvasculature, impairing organ perfusion. This is why TAMOF behaves like TTP downstream — even though the trigger is infection or inflammation rather than autoimmunity. It is not primarily a bleeding disorder. It is not primarily a consumptive coagulopathy. It is a microvascular platelet process with systemic consequences. How the Labs Tell the Story TAMOF rarely declares itself with a single decisive test. Instead, it reveals itself through converging laboratory signals, each nudging the differential toward microangiopathy. LDH  is often elevated, reflecting both microangiopathic hemolysis and tissue ischemia from small-vessel thrombosis. In isolation, this finding is nonspecific. In context — alongside falling platelets and worsening organ function — it becomes meaningful. Haptoglobin  may be low, but normal values do not exclude TAMOF. Inflammatory states raise baseline haptoglobin levels, which can mask hemolysis. Trends and correlations matter more than absolutes. Peripheral smear  findings can support the diagnosis, but they are often subtle. Schistocytes may be present — sometimes sparsely, sometimes clearly — depending on the degree of microangiopathic hemolysis. Coagulation studies  are especially useful for what they don’t  show. In TAMOF, PT and aPTT are often normal or only mildly prolonged, fibrinogen is typically preserved, and bleeding is uncommon. This profile argues against overt DIC and redirects attention away from primary consumptive coagulopathy. ADAMTS13: Severity Without a Shortcut ADAMTS13 activity in TAMOF spans a wide range. Levels may be modestly reduced, markedly decreased, or — in some cases — severely deficient, with accompanying schistocytosis and overt microangiopathic hemolysis. What distinguishes TAMOF from classic immune-mediated TTP is not the absolute ADAMTS13 level, but the mechanism of deficiency. In TAMOF, reduced ADAMTS13 reflects: Consumption during systemic endothelial activation Inflammatory inhibition of enzyme activity Reduced hepatic synthesis of ADAMTS13 Even when ADAMTS13 activity is severely reduced, the process is typically secondary to inflammation or sepsis, rather than autoantibody-mediated. Rigid thresholds can mislead. An ADAMTS13 level interpreted in isolation may obscure the diagnosis rather than clarify it. Context matters. Narrowing the Differential Taken together, this laboratory pattern helps distinguish TAMOF from its closest mimics: Versus DIC: preserved coagulation parameters and a platelet-driven microangiopathic picture argue against primary consumption. Versus classic TTP: an inflammatory trigger and secondary mechanism of ADAMTS13 deficiency point away from immune-mediated disease, even when the downstream effects overlap. Versus “just sepsis”: progressive thrombocytopenia, rising LDH, and organ dysfunction out of proportion to hemodynamics suggest something more than cytokines alone. No single lab makes the diagnosis. But the pattern does. Why Plasma Exchange Makes Sense Once TAMOF is recognized as a thrombotic microangiopathy, the rationale for therapeutic plasma exchange becomes clear. Plasma exchange functions in TAMOF much as it does in TTP: Replenishing ADAMTS13 Removing ultra-large and high-molecular-weight von Willebrand factor multimers Reducing circulating inflammatory mediators that perpetuate endothelial injury The trigger differs. The downstream pathophysiology does not. When TAMOF is dismissed as “just sepsis” or mislabeled as DIC, the opportunity for targeted intervention narrows. Early recognition turns an otherwise nebulous complication into a treatable process. A Final Lab-Centered Takeaway TAMOF is not rare because it is uncommon. It is rare because we don’t look for it. For those of us in laboratory medicine, this is where our value is clearest — not in reporting isolated numbers, but in helping clinicians see how those numbers fit together. Sometimes the diagnosis isn’t hidden. It ’s just fragmented — waiting for someone to assemble the story.

I learned something new this week: you can buy an at-home ABO blood typing kit on Amazon. I didn’t know that. And I suspect many transfusion medicine physicians don’t either. I found out when a pediatrician called with a worried question. A newborn’s blood type had been determined appropriately in the hospital: A negative . The mother’s type was known: O negative . The father reported he was O negative , based on an at-home blood typing kit. The parents were now concerned about non-paternity. At first glance, this looks like a classic ABO inheritance problem. Two O parents should not have an A child. But the problem wasn’t genetics — it was data quality. The father’s blood type was not actually known. What at-home ABO typing really tells you Consumer ABO kits perform forward typing only, using fingerstick blood applied to anti-A and anti-B reagents, with visual interpretation by the user. They do not  include: Reverse typing Internal concordance checks Trained interpretation Safeguards against weak reactions, drying artifact, or clotting These kits are widely available online and are not FDA-cleared diagnostic tests. They do not  reliably determine a person’s blood type. The most likely explanation is also the least dramatic The simplest explanation was that the father is not type O. One particularly plausible possibility is blood group A2. About 20% of people with blood group A are A2, translating to roughly 4–8% of the general population, depending on ancestry. A2 red cells express fewer A antigens and may show weak or absent agglutination with some anti-A reagents, especially outside a controlled laboratory setting. Critically: A2 individuals are identified on reverse typing, by the presence of anti-A1 At-home kits do not include reverse typing Newborn hospital testing does  include appropriate confirmatory methods So an A2 father could easily misinterpret a forward-only home test as “O,” while the newborn’s A type is correctly identified. No exotic genetics required. Other mundane failure modes Even without A2: Weak agglutination may be misread as negative Drying artifact can obscure reactions Fingerstick clotting or poor mixing can alter appearance User interpretation error is common, even among trained staff This is precisely why laboratory ABO determination relies on redundancy and safeguards, not a single visual read. Why this matters clinically ABO typing feels deceptively simple. Most people learn their blood type early and treat it as a personal identifier. That familiarity makes it especially vulnerable to misunderstanding. When an at-home test says “O,” people don’t hear: this is a forward type screen without confirmation. They hear: I know my blood type. In this case, a testing limitation nearly became a family crisis. The ethical risk Non-paternity should never be raised on the basis of an unvalidated consumer test. The risk here isn’t the existence of these kits — it’s clinicians being unaware of them and their failure modes. A simple rule If a patient says: "I know my blood type - I tested it at home." The response should be calm and direct: “At-home blood typing kits are not reliable. If needed, we can determine your blood type properly through a laboratory.” No speculation. No escalation. Why transfusion medicine should know this exists This issue won’t appear in hemovigilance reports or quality dashboards. It will surface quietly as: Pediatric questions Awkward counseling conversations Family anxiety Recognizing at-home ABO typing for what it is allows us to de-escalate quickly and prevent harm that has nothing to do with biology. I didn’t know these kits were being marketed. Now I do. And next time, I’ll recognize the problem immediately — not as a mystery of inheritance, but as a reminder that laboratory safeguards are part of the test.

Donor infectious disease eligibility is one of those topics that feels straightforward until you’re asked to explain why  a donor with negative testing still isn’t eligible — or why some pathogens get NAT, others don’t, and some only get tested once. This post walks through donor eligibility the way the boards expect you to understand it: as a risk-assessment framework , not just a checklist of tests. What Is Donor Infectious Disease Eligibility? Donor eligibility  is the assessment of a donor’s risk of transmitting infectious disease to a recipient. Its purpose is recipient protection and it is based on two pillars: Donor history Laboratory testing This is distinct from donor suitability , which focuses on donor safety (for example, hemoglobin thresholds or procedural tolerance). A donor can be suitable but not  eligible — and vice versa. How Donor Eligibility Is Determined The Donor History Questionnaire (DHQ) The DHQ evaluates risks that laboratory testing alone cannot fully capture, including: Symptoms of infection Behavioral risk factors Travel and residence history Exposure history (blood, needles, sexual contact) Testing does not  eliminate window-period risk, and emerging pathogens may not yet have validated screening assays. As a result, negative testing does not equal eligibility  when exposure risk is recent. The Window Period (Why History Still Matters) The window period  is the time between infection and when that infection becomes detectable by testing. Even with modern NAT-based screening, window periods still exist. This is why donor history remains a critical component of eligibility determination. Infectious Disease Screening: The Tests (What We Use and Why) All allogeneic donors undergo infectious disease screening using serologic testing, nucleic acid testing (NAT), or both . The strategy used for each pathogen reflects its biology: duration of viremia, durability of antibody response, prevalence, and the clinical consequences of transmission. HIV-1/2 Serology HIV-1/2 antibody HIV-1 p24 antigen NAT HIV-1 RNA Window Period NAT: 9–11 days Serology: 15–20 days Notes Layered NAT and Ag/Ab screening minimizes window-period transmission, making residual transfusion-transmitted HIV risk extremely low. However, there is no licensed HIV-2 NAT test in the U.S. , so HIV-2 detection relies entirely on serology. Hepatitis B Virus (HBV) Serology HBsAg Anti-HBc NAT HBV DNA Window Period NAT: 20–22 days Serology: 30–38 days Notes HBV has the longest residual transfusion risk  among routinely screened viral infections due to low-level, intermittent viremia . Triple-layer testing mitigates occult and low-level infection but does not eliminate risk entirely. Hepatitis C Virus (HCV) Serology Anti-HCV NAT HCV RNA Window Period NAT: 3–5 days Serology: 50–70 days Notes Universal NAT has nearly eliminated window-period HCV transmission. Anti-HCV testing is notorious for false positives , which is why donor re-entry policies matter. HTLV-I/II Serology Anti-HTLV-1/2 NAT Not performed Window Period Serology: 45–60 days Notes HTLV infection is chronic with a durable antibody response, enabling serology-only screening. HTLV-1 is associated with adult T-cell leukemia/lymphoma . The screening strategy reflects low prevalence , not a short window period. West Nile Virus (WNV) Serology Not performed NAT WNV RNA Window Period NAT: 6–10 days Notes Short viremia necessitates NAT-only, seasonally adaptive screening . Serology is not useful for donor screening in acute infection. Syphilis ( Treponema pallidum ) Serology Treponemal antibody test Non-treponemal test NAT Not performed Window Period Serology: 10–30 days Notes T. pallidum  survives poorly in refrigerated blood, making transfusion transmission rare but documented. Treponemal antibodies persist long after infection and treatment, which is why syphilis is a key context for donor re-entry . Trypanosoma cruzi  (Chagas Disease) Serology Antibody testing only NAT Not performed Window Period Serology: 3–8 weeks Notes Chronic infection with durable antibodies enables one-time serologic screening . Transmission is rare but serious and linked to donors with residence in endemic areas. Babesia Serology Not performed NAT Babesia  DNA Window Period NAT: 7–14 days Notes Persistent asymptomatic parasitemia necessitates regional NAT screening . Babesia  is a leading cause of fatal transfusion-transmitted infection in the U.S. , with required testing in endemic regions including the Northeast and Upper Midwest . Deferrals: Temporary vs Indefinite Temporary deferrals  apply when risk decreases with time Indefinite deferrals  apply when risk does not meaningfully decrease Examples include: Temporary: recent tattoo, recent exposure, acute illness Indefinite: HIV, chronic HBV, HCV, HTLV, vCJD risk High-Yield Deferral Periods (Boards Love These) Some deferrals are particularly high yield because they test whether you understand current , risk-based policy rather than outdated rules. Malaria Travel to endemic area (no illness): 3-month deferral Residence in endemic area or prior malaria: 2-year deferral High-Risk Sexual Behavior or Injection Drug Use Universal 3-month deferral Applies regardless of gender or sexual orientation Incarceration >72 hours: 12-month deferral <72 hours: No deferral Tattoos State-licensed facility: No deferral Non-state-licensed facility: 3-month deferral vCJD-Related Risks Residence in Great Britain or Europe: No deferral Use of bovine growth hormone: Indefinite deferral Cadaveric dura mater transplant: Indefinite deferral Donor Eligibility Potpourri (The Real-World Stuff) Donor Re-Entry Donor re-entry allows individuals with false-positive screening tests  to become eligible to donate again. This process: Is pathogen-specific Is regulated by the FDA Requires repeat testing on a subsequent donation Confirmed infections generally preclude re-entry, with syphilis (after full treatment)  being the main exception. Product Look-Backs Product look-backs occur when a donor is later found to have a positive infectious disease test. All donations during a defined prior period must be investigated to determine: Whether products were transfused Whether recipient notification or testing is required For boards: Look-backs are mandated for HIV-1/2 and HCV The required look-back period is 12 months prior to the positive test Special Donor Populations Directed Donors Must meet the same infectious disease eligibility criteria No relaxation of standards If unused, products may be returned to general inventory Autologous Donors Minimum hemoglobin: >11 g/dL Collection must occur >72 hours before surgery Requires physician order Infectious disease testing may vary by institutional policy If unused, products are discarded Regulatory Oversight: Who Sets the Rules? FDA Establishes laws and regulations 21 CFR 630 governs donor infectious disease testing AABB Interprets FDA regulations into operational standards Maintains the Donor History Questionnaire Understanding who  regulates what  matters — especially when policies change. Consolidated Board Pearls The Basics Define the window period → Time between infection and detection What does DHQ stand for? → Donor History Questionnaire Infectious Disease Screening Name 3 pathogen classes not directly tested → Most bacteria, most parasites, prion diseases Screening Tests Most common fatal transfusion-associated infection? → Babesia HIV-1/2 NAT window period? → 9–11 days Virus with longest residual transfusion risk? → HBV Deferrals Universal deferral period for high-risk behavior? → 3 months Deferral for incarceration <72 hours? → None Deferral for cadaveric dura mater transplant? → Indefinite Eligibility Potpourri Mandated look-back period for HIV? → 12 months What is donor re-entry? → Process allowing donors with false-positive tests to donate again If a directed unit is unused, must it be discarded? → No, it may enter general inventory

Stem cell collection sits at the intersection of hematology, immunology, and procedural medicine. It’s conceptually simple — collect enough hematopoietic stem cells to reconstitute marrow — but operationally complex, with decisions at every step that affect engraftment, toxicity, and long-term outcomes. This post walks through stem cell collection from a practical, systems-level perspective: what we collect, where it comes from, how we mobilize it, and what determines whether a transplant succeeds. The Big Picture: What Are We Collecting? At the center of stem cell transplantation are hematopoietic stem cells (HSCs)  — most commonly identified clinically as CD34-positive cells . These cells are capable of: Self-renewal Differentiation into all mature blood lineages Clinically, we collect them for three main purposes: Autologous transplant , where patients receive their own cells back after myeloablative therapy Allogeneic transplant , where donor cells replace a recipient’s marrow Marrow rescue  following intensive chemotherapy While multiple sources exist, modern practice overwhelmingly favors peripheral blood collection. Where Stem Cells Come From Peripheral Blood Peripheral blood stem cells are now the dominant source for both autologous and allogeneic transplants. They: Yield higher CD34+ cell counts Engraft faster than bone marrow Are collected via apheresis rather than surgery The tradeoff, particularly in the allogeneic setting, is a higher risk of graft-versus-host disease (GVHD) . Bone Marrow Bone marrow harvests are obtained directly from the iliac crests under anesthesia. Compared with peripheral collections, they: Require invasive access Contain more red blood cell contamination Carry higher risk of contamination with skin flora They are used less frequently but remain relevant in specific clinical contexts. Cord Blood Cord blood is largely peripheral to apheresis practice but remains board-relevant. It is: Cryopreserved and banked long-term More tolerant of HLA mismatch Limited by lower total cell dose, sometimes requiring multiple units or ex vivo expansion Mobilization: Getting Stem Cells Into the Blood Under normal conditions, hematopoietic progenitor cells reside in the bone marrow niche, where adhesion molecules and chemokine gradients keep them anchored and quiescent. Mobilization disrupts that relationship. Key mechanisms include: CXCR4–CXCL12 (SDF-1α) signaling , which tethers stem cells to marrow stroma Soluble factors such as stem cell factor Proteases and neurotransmitter-mediated signals The most commonly used mobilizing agent is G-CSF , which indirectly alters the marrow microenvironment and increases circulating CD34+ cells. Plerixafor (AMD3100, Mozobil)  works differently: it directly inhibits CXCR4, rapidly releasing stem cells into the peripheral circulation. This is particularly useful in poor mobilizers. How We Collect Stem Cells Apheresis Peripheral blood stem cells are collected via leukapheresis , using continuous-flow cell separators. The procedure: Processes large blood volumes Uses ACD-A  as the anticoagulant Selectively collects mononuclear cells enriched for CD34+ cells This is the most common and operationally efficient collection method. Bone Marrow Harvest Bone marrow collection involves multiple passes through skin and cortical bone. Compared with apheresis, it: Has higher contamination risk Produces products with more RBCs Carries procedural risks such as bleeding and post-procedure anemia How Much Is Enough? Target Cell Dose Cell dose matters — both for engraftment speed and downstream complications. Autologous transplant Minimum effective dose: ~2 × 10⁶ CD34+ cells/kg Optimal dose: 4–6 × 10⁶ CD34+ cells/kg Allogeneic transplant Similar target range Higher doses improve engraftment but increase GVHD risk Collection strategies often balance donor safety, collection efficiency, and the marginal benefit of additional cells. Complications of Stem Cell Collection Citrate Toxicity (Most Common) ACD-A chelates calcium, leading to hypocalcemia. Symptoms range from: Perioral tingling and paresthesias Tetany Cardiac arrhythmias in severe cases Management includes oral or IV calcium supplementation and slowing the collection rate. Vascular Access Issues Central venous catheters carry risks of: Infection Thrombosis Bleeding Donor-Specific Issues Allogeneic donors may experience G-CSF-related side effects, most commonly bone pain and headache. Donor safety always takes precedence over collection yield. Bone Marrow Harvest Complications These include local site pain, bruising, hematoma formation, and anemia. Autologous vs Allogeneic Collection: Why the Difference Matters Autologous transplants avoid GVHD but lack graft-versus-tumor effects. Allogeneic transplants introduce immunologic risk — but also therapeutic benefit. This balance drives donor selection, conditioning regimens, and post-transplant monitoring. Infectious Disease Testing and Product Handling All stem cell products require infectious disease screening, including: HIV HBV HCV HTLV Syphilis Product handling differs by transplant type: Autologous products  are typically cryopreserved Allogeneic products  may be infused fresh or frozen Cryopreservation Basics DMSO  is the most common cryoprotectant Controlled-rate freezing  precisely regulates temperature to prevent intracellular ice crystal formation Passive freezing  uses insulated containers and −80 °C storage but offers less control Engraftment: The Endpoints Everyone Cares About Boards — and clinicians — care deeply about engraftment definitions: Neutrophil engraftment: ANC > 500 for 3 consecutive days Platelet engraftment: Platelets > 20,000 without transfusion support for 7 days These metrics anchor post-transplant monitoring and outcome reporting. Consolidated Board Pearls Stem Cell Sources Which source has the most CD34+ cells? → Peripheral blood Highest GVHD risk? → Peripheral blood Faster engraftment than marrow? → Yes Mobilization Mechanism of plerixafor? → CXCR4 inhibition Most commonly used mobilizing agent? → G-CSF Collection Highest contamination risk with skin commensals? → Bone marrow harvest Most common collection method? → Apheresis Target Dose Minimum effective dose? → 2 × 10⁶ CD34+ cells/kg Benefit of higher dose? → Faster engraftment Risk of higher dose? → GVHD Apheresis Complications Most common anticoagulant? → ACD-A Mechanism? → Calcium chelation Most common side effect? → Hypocalcemia Treatment? → Calcium supplementation Most common G-CSF side effect? → Bone pain Autologous vs Allogeneic Risk of allogeneic transplant? → GVHD Benefit? → Graft-versus-tumor effect Product Handling Most common cryoprotectant? → DMSO Why controlled-rate freezing? → Prevents intracellular ice crystals Engraftment Neutrophils: ANC > 500 for 3 days Platelets: >20k without transfusion for 7 days